Compare LICN & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LICN | DARE |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 16.6M |
| IPO Year | 2021 | 2014 |
| Metric | LICN | DARE |
|---|---|---|
| Price | $0.86 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 11.7K | ★ 187.9K |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,807,885.00 |
| Revenue This Year | N/A | $163.80 |
| Revenue Next Year | N/A | $226.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $0.69 |
| 52 Week High | $9.49 | $3.78 |
| Indicator | LICN | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 32.11 | 36.65 |
| Support Level | $0.75 | $0.70 |
| Resistance Level | $1.12 | $0.88 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 17.57 | 2.40 |
Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational, and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and the sales of financial and taxation training software.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.